SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between…
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between…
The first patient was dosed in the Phase 1 dose escalation trial of CTX-8371.This study is conducted in patients with…
Halifax, Nova Scotia--(Newsfile Corp. - April 12, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona")…
The Food and Drug Administration approves CAR T-Cell therapy Abecma as a second-line treatment and the CAR T-Cell therapy Carvykti…
Data and Safety Monitoring Board (DSMB) recommends the continuation, without modifications, of the adaptive Phase 2b/3 NAVIGATE study of belapectin…
WATERTOWN, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to…
SHANGHAI, China, April 07, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a…
NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic…
Expect Topline Data for Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab for Alzheimer’s Disease in Q3 2024 Company raised $17.9 million…